Stem Cells From Cord Blood Provide Hope for Cure

Published Online: Tuesday, July 10, 2012
Follow Pharmacy_Times:
A study published earlier this year in BioMed Central by Yong Zhao, MD, PhD, and colleagues shows a promising possibility for a cure to type 1 diabetes in patients with moderate to severe disease. Fifteen patients participated in this phase 1/phase 2 trial focused on a novel approach to treatment: use of the Stem Cell Educator—a device that functions to “reeducate” lymphocytes to stop attacking betaislet cells so they can grow and secrete insulin.

The Stem Cell Educator is a device that is lined with stem cells derived from cord blood. The blood of a patient with diabetes is run through a blood separator. This separator removes lymphocytes from whole blood, which would be returned back to the patient. The separated lymphocytes then enter the Stem Cell Educator for 2 to 3 hours before being returned to the patient. It is important to note that the patient’s own lymphocytes are returned to him/her and no stem cells from the cord blood are received.

Insulin requirements decreased dramatically and A1C levels improved in study patients. Results were sustained throughout the entire study duration. No study patient had any adverse effects. Because foreign stem cells do not enter the patient, human leukocyte antigen matching is not required, nor is there a risk for graft versus host disease. A big step toward the cure, ex vivo lymphocyte education provides hope not just for diabetes, but for a vast array of other autoimmune disorders as well.

To read more articles in this watch, click here:
Coffee Consumption and Type 2 Diabetes Risk Reduction
L
inks Explored Between Childhood Diet and Type 1 Diabetes


Related Articles
Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.
Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.
Many patients with non-alcoholic fatty liver disease also have low vitamin D levels.
Several studies have reported that controlling blood pressure with medication improves cardiovascular outcomes.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$